AerMedx Health

Raising a $1M seed equity round to file a 510(k) and obtain initial human clinical data

Facebook Twitter LinkedIn

 
SUMMARY

Medical Device start-up developing a novel Cold Atmospheric Plasma bio-molecule deposition system to speed healing and prevent infections.   

AerMedx Health’s Cold Atmospheric Plasma Deposition System is a major advancement in local drug delivery for faster healing and infection treatment.  It enables the non-systemic delivery of pure biologics or drugs which are bonded to almost any surface.  The AerMedx therapy is a breakthrough treatment for multiple conditions including faster healing of burns, abrasions, Diabetic Foot Ulcers & Venous Stasis Ulcers.  It also prevents and treats infections with topical delivery of antibiotics directly to tissue.
 
STAGE

  • Prototype ready, design frozen, animal data, validation testing phase.  
  • Preparing 510(k) for submission to FDA in Q3 2020. 
  • Dermatology product commercialization Q2 2021.   
  • Diabetic Foot Ulcer Commercialization Q4 2021
 
TECHNOLOGY
  • Promotes cell proliferation and healing 
  • Applies wide range of biologics or drugs
  • Bonds to almost any tissue and bone
  • Kills bacteria, viruses, spores, biofilms 
 
ACCOMPLISHMENTS
  • Joint Development and Commercialization Agreement with Apyx Medical (formerly Bovie Medical)
  • Design of plasma/biologic delivery system frozen
  •  Preparing for human clinical trials
  • Validation of 12 active biologic materials bonded to tissues or device surfaces – proteins, antibiotics, polysaccharides, enzymes, human cells
  • Highly successful animal trials
    • Diabetic ulcer treatment 
    • Antibiotic treatment of orthopedic infection
    • Accelerated burn healing
  • 2 broad patents issued - 3 additional applications with office actions

Ready to Ask For Funding for your company?

Post a Funding Request

AerMedx Health is no longer seeking funding.